APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 1882, The Fair and Immediate Release of Generics Act S. 27, the Preserve Access to Affordable Pharmaceuticals Act S. 3187.PCS/ES, the Food and Drug Administration Safety and Innovation Act, Title XI, Other Provisions, Subtitle C, Miscellaneous Provisionsm Section 1131, Drug Development and Testing Establishment of a federal track and trace system for pharmaceuticals HR 6322, the FDA User Fee Corrections Act of 2012 Actelion Pharmaceuticals LTD and Actelion Clinical Research Inc. v. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc.
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Shermfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.